Navigation Links
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Date:8/30/2007

MISSISSAUGA, ON, Aug. 30 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. ("YM-USA") has been cleared by the US Food and Drug Administration (FDA) to initiate a Phase II trial investigating nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG), a form of inoperable, treatment-resistant brain cancer. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Eight leading US pediatric clinical centers will be participating in the study. YM BioSciences previously announced that it had received a No Objection Letter from Health Canada in June 2007 to initiate this single-arm trial, which will enrol 44 patients with DIPG who will be treated with nimotuzumab as monotherapy.

This is the first occasion, to the knowledge of the Company, in which a clinical trial has been cleared by the FDA for a drug of Cuban origin. Clearance for importation of nimotuzumab into the US for this trial was authorized by a Special License issued to YM-USA by the US Treasury Department's Office of Foreign Assets Control (OFAC). Nimotuzumab has already been administered to a number of children in the US under licenses from the US Treasury Department and under single-patient INDs from the FDA.

"The clearance of this US IND by the FDA is a significant step in the development of nimotuzumab," said David Allan, Chairman and CEO of YM BioSciences. "In addition to the US investigatory sites, the global development program for nimotuzumab includes o
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... Technology Center (HTC), Texas, largest technology incubator and ... of Entrepreneurs . "  The event honored local entrepreneurs ... economy; and developed lifesaving and revolutionary technologies. ... TechTrans International, Inc., as this year,s honoree. As the Founder ...
... May 20, 2012 A team of Australian scientists has ... of people with bowel cancer. The discovery has ... would signal the early stages of bowel cancer. This test ... programs and encouraging those at risk to have a colonoscopy. ...
... NEW YORK, May 17, 2012   Pharmaceutical companies ... value could have an advantage in the competition for ... published today by the Health Research Institute (HRI) at ... to know how well a drug will work and ...
Cached Biology Technology:Leading Technology Incubator Honors Extraordinary Entrepreneurs 2Leading Technology Incubator Honors Extraordinary Entrepreneurs 3Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer 2Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer 3New Competitive Arena Emerges for Pharmaceutical Companies in Healthcare's Changing Payment Landscape, Finds PwC Health Research Institute Study 2New Competitive Arena Emerges for Pharmaceutical Companies in Healthcare's Changing Payment Landscape, Finds PwC Health Research Institute Study 3New Competitive Arena Emerges for Pharmaceutical Companies in Healthcare's Changing Payment Landscape, Finds PwC Health Research Institute Study 4New Competitive Arena Emerges for Pharmaceutical Companies in Healthcare's Changing Payment Landscape, Finds PwC Health Research Institute Study 5New Competitive Arena Emerges for Pharmaceutical Companies in Healthcare's Changing Payment Landscape, Finds PwC Health Research Institute Study 6
(Date:8/21/2014)... WHEN: , Saturday to Wednesday, Oct. 18-22, 2014 ... 111 W. Harbor Drive, San Diego, CA 92101 ... sessions and other presentations of the latest research ... Opening plenary session featuring high-scoring abstracts on rare ... of various cancers, and treatment for sun sensitivity ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
(Date:8/20/2014)... 158 pregnant teenagers in Rochester, NY, nearly half engaged ... ice, cornstarch, vacuum dust, baby powder and soap, and ... Moreover, such teens had significantly lower iron levels as ... , Pregnant teens, regardless of pica, are at higher ... deficiency and anemia. Low iron in pregnant teens raises ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Water and sunlight the formula for sustainable fuel 2Pica in pregnant teens linked to low iron 2
... HOUSTON -- A comprehensive drug development strategy that ... then narrows down to a small-molecule prototype has yielded ... ways, a team led by scientists at The University ... two papers published back-to-back online at the Proceedings ...
... to detect nuclear explosions and enforce the world,s nuclear ... volcanoes in the Northern Mariana Islands near Guam. The ... for forward deployment of U.S. military forces in the ... U.S. Geological Survey and Southern Methodist University in Dallas ...
... provide powerful protection against risks her baby faces in the ... the journal Biological Psychiatry . The research shows that ... to be a harbinger for babies, poor cognitive development ... care during infancy and toddler-hood. The new study represents ...
Cached Biology News:New strategy develops 2 prototype drugs against cancer, retinal diseases 2New strategy develops 2 prototype drugs against cancer, retinal diseases 3Volcano monitoring will target hazard threat to Marianas, US military and commercial jets 2Volcano monitoring will target hazard threat to Marianas, US military and commercial jets 3Volcano monitoring will target hazard threat to Marianas, US military and commercial jets 4Good parenting triumphs over prenatal stress 2Good parenting triumphs over prenatal stress 3
... RNase H- Reverse Transcriptase ... version of SuperScript™ II ... SuperScript™ II it synthesizes ... from single-stranded RNA DNA ...
versican (H-56)...
... Heraeus HERAcell is the ideal CO2 incubator ... of ova or embryos at or near ... to provide everything needed to protect and ... Safe and stable incubation conditions ensure optimum ...
... presents PsiPort Mass Directed Auto Purification ... data acquisition system designed for automated ... life science and pharmaceutical discovery programs. ... to simplify high throughput mass directed ...
Biology Products: